Abstract #0776
Psychostimulant Medication Duration Correlates with Increased Brain Iron Levels in Attention-Deficit/Hyperactivity Disorder
Vitria Adisetiyo 1 , Jens H. Jensen 1 , Ali Tabesh 1 , Rachael L. Deardorf 1 , Kevin M. Gray 2 , and Joseph A. Helpern 1,3
1
Radiology and Radiological Science, Center
for Biomedical Imaging, Medical University of South
Carolina, Charleston, SC, United States,
2
Psychiatry
and Behavioral Sciences, Medical University of South
Carolina, Charleston, SC, United States,
3
Neuroscience,
Medical University of South Carolina, Charleston, SC,
United States
Dopamine (DA) deficiency is implicated in
attention-deficit/hyperactivity disorder (ADHD) and is
treated with psychostimulant medications that increase
synaptic DA. Given that brain iron is required for DA
metabolism and can be measured non-invasively with MRI,
we examined brain iron as a potential indirect biomarker
of DA status. Using magnetic field correlation imaging
and R2*, we found comparable brain iron levels in
controls and psychostimulant-medicated ADHD patients.
Unlike controls, brain iron in patients did not increase
with age but rather increased as a function of
psychostimulant medication duration suggesting that
longer psychostimulant treatment may normalize brain
iron levels in ADHD patients.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
